-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US00032Q1040 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 95M |
|---|---|
| PE Ratio | None |
| Beta | 0.34 |
| Target Price | 2 |
| Dividend Yield | None |
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AADI using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026